Table 2.
The effect of risk factors on development of myocardial dysfunction (SF < 29 %) – Univariate and multiple logistic regression analysis
| Risk Factorsa, b | Unadjusted OR | 95 % CI | p-value | Adjusted OR | 95 % CI | p-value |
|---|---|---|---|---|---|---|
| Years post-chemo | 0.99 | 0.96, 1.00 | 0.87 | --- | --- | --- |
| Age at Diagnosis | 1.04 | 1.00, 1.08 | 0.04 | 1.00 | 0.96, 1.05 | 0.99 |
| Gender | 1.16 | 0.74, 1.83 | 0.51 | --- | --- | --- |
| Cumulative dose | 3.36 | 2.06, 5.49 | <0.001 | 3.27 | 1.94, 5.49 | <0.001 |
| Radiation to chest | 1.82 | 0.99, 3.33 | 0.05 | 1.50 | 0.76, 2.96 | 0.24 |
| Vinca Alkaloids | 0.80 | 0.46, 1.37 | 0.41 | --- | --- | --- |
| BMT | 2.98 | 1.57, 5.64 | 0.001 | 2.57 | 1.24, 5.30 | 0.01 |
| Previous heart diseasec | 2.09 | 1.05, 4.15 | 0.04 | 1.87 | 0.85, 4.12 | 0.12 |
| Cardio-protective drugs | 1.86 | 0.80, 4.32 | 0.15 | --- | --- | --- |
aRisk factors for cardiotoxicity include increased length of post-chemotherapy interval (years), younger age at diagnosis, female gender, total cumulative dose ≥240 mg/m2, radiation therapy to the chest, treatment with vinca alkaloids, bone marrow transplant, previous heart disease, non-use of cardio-protective drugs
bThe 5 significant risk factors upon univariate analysis were selected as covariates for the multiple logistic regression model (younger age at diagnosis, total cumulative dose anthracyclines > 240 mg/m2, radiation to the chest, BMT and previous heart disease)
cPrevious heart disease defined as: presence of congenital heart disease, pericardial effusion/tamponade, SVC syndrome, myocardial dysfunction prior to chemotherapy